Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 9/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1732996 | 0.89 | PPARD (0.52) | PPARDFFAR1TP53PTGDR2MAPT | |
| SCHEMBL4847898 | 0.84 | NPC1 (0.48) | NPC1POLBRAB9APTGDR2GAA | |
| SCHEMBL4854113 | 0.82 | PPARD (0.53) | PPARDFFAR1TP53NPC1RAB9A | |
| SCHEMBL31725848 | 0.76 | NPC1 (0.63) | NPC1POLBRAB9AMAPTLMNA | |
| SCHEMBL698056 | 0.76 | NPC1 (0.63) | NPC1POLBRAB9AMAPTLMNA | |
| SCHEMBL4851206 | 0.75 | PPARD (0.44) | PPARDFFAR1TP53POLBMAPT | |
| SCHEMBL6243768 | 0.75 | PPARD (0.73) | PPARDFFAR1MAPT | |
| SCHEMBL2097759 | 0.74 | FFAR1 (0.53) | PPARDFFAR1TP53NPC1RAB9A | |
| SCHEMBL4038141 | 0.74 | KDR (0.67) | PPARDFFAR1TP53NPC1POLB | |
| SCHEMBL3077683 | 0.74 | SMN1; SMN2 (0.56) | PPARDFFAR1TP53NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368578-B2 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20060135578-A1 | Five-membered heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1541564-A1 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135578-A1 | Five-membered heterocyclic compounds | GPR119, OR10J3, CYP11B1 | PPARD 745/4885FFAR1 771/4885TP53 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.